Affiliation:
1. Department of Pharmaceutics, Girijananda Chowdury Institute of Pharmaceutical Science, Hatkhowapara, Azara, Guwahati, Assam, India. Pin code: 781017.
Abstract
Cancer is the second leading cause of death in the world and one of the major public health problems. Despite the great advances in cancer therapy, the incidence and mortality rates of cancer remain high. Therefore, the goal for more efficient and less toxic cancer treatment strategies is still at the forefront of current research. Despite these efforts, cancer drug research remains a remarkably challenging field, and therapeutic innovations have not yet achieved expected clinical results. However, the physiopathology of the disease is now better understood, and the discovery of novel molecular targets has refreshed the expectations of developing improved treatments. Paclitaxel (PCT) is a chemotherapeutic agent used as a first-line treatment for a wide range of cancers, such as lung, ovarian, breast, prostate, head, and neck cancers, and AIDS-related Kaposi sarcoma. Currently, the marketed forms of Paclitaxel are intravenous formulations. Oral administration of Paclitaxel is unfortunately hampered due to its low bioavailability. This is explained by its low aqueous solubility, low permeability, high affinity for cytochrome P450 and P-glycoprotein. As another approach, drug carrier systems are extensively studied to enhance oral Paclitaxel bioavailability and reduce side effects. The niosomes provides several important advantages over conventional drug therapy. Structurally, niosomes are similar to liposomes, in that they are also made up of a bilayer. However, the bilayer in the case of niosomes is made up of non-ionic surface-active agents rather than phospholipids as seen in case of liposomes. Niosome nanoparticles are among these drug delivery systems, which have numerous applications in drug delivery and targeting. Niosomes are frequently used for loading drugs serving different purposes (e.g., anticancer, antiviral, and antibacterial agents). The aim of this review is to evaluate the extent of nanotherapeutics used in anti-cancer activity.
Subject
Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference58 articles.
1. Roger Walker, Clive Edwards. Cancer disease. In Roger Walker, The Textbook of Clinical pharmacy and Therapeutics, Third Edition. New Delhi, Jaypee Brothers Medical Publishers [P] Ltd. 2003; 265-353.
2. Peppa LB, Blanchette JO. Nanoparticle and targeted system for cancer therapy. Adv Drug Deliv Rev. 2004; 56: 1649-1659. https://doi.org/10.1016/j.addr.2004.02.014
3. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochem Biophys Acta. 1995; 1233: 134-144. https://doi.org/10.1016/0005-2736(94)00235-h
4. Katragadda U, Fan W, Wang Y, Teng Q, Tan C. Combined delivery of Paclitaxel and Tanespimycin via micellar nanocarriers: pharmacokinetics, efficacy and metabolomic analysis. 2013; 8(3): e58619. https://doi.org/10.1371/journal.pone.0058619
5. Jang SH, Wientjes MG, Au JLS. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule. J Pharmacol Exp Ther. 2001; 296: 1035-1042
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献